The Growing Antimicrobial Resistance Challenge

Antimicrobial resistance (AMR) is a major threat to Public Health. According to the World Health Organization, there are an estimated 700,000 deaths worldwide each year as a result of bacterial infections. The US Center for Disease Control and Prevention (CDC) estimates that in the US alone, 23,000 people die each year from drug-resistant bacterial infections.

Global Movement to Combat Antimicrobial Resistance

CARB-X is one of the world’s largest public-private partnerships dedicated to accelerating antibacterial innovation. It has the world’s largest antibacterial pipeline focused specifically on combating drug resistant bacteria, especially Gram-negative bacteria, and it supports research projects in companies around the world. CARB-X is investing more than $500 million between 2016-2021 in the development of antibiotics and other life-saving therapeutics of all types, diagnostics, vaccines and other preventatives and devices. California Life Sciences Institute (CLSI) is a vital part of CARB-X’s network of accelerators and provides business and technical support to funded projects throughout the world.

To learn more about CARB-X and funding opportunities, please consult the CARB-X website at https://carb-x.org/

We would be happy to answer your questions about CARB-X and share more ways you can get involved.
Julie Harness
Sr. Director

Assistant Secretary for Preparedness and Response Barda Wellcome Trust NIH NIAID
California Life Sciences Institute Mass Bio Boston University RTI Broad Institute